Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAH Cardinal Health	$156.37 -0.2%	$152.03	$106.98 ▼ $168.44	$37.12B	0.71	2.42 million shs	17,341 shs
COR Cencora	$307.20 -0.5%	$295.45	$220.03 ▼ $315.23	$59.61B	0.63	1.56 million shs	14,186 shs
LLY Eli Lilly and Company	$851.33 +0.9%	$736.97	$623.78 ▼ $937.00	$806.14B	0.47	4.10 million shs	130,460 shs
MCK McKesson	$748.83 -0.2%	$704.07	$492.39 ▼ $776.14	$92.93B	0.52	868,717 shs	13,491 shs
NVS Novartis	$132.85 +1.0%	$124.18	$96.06 ▼ $133.55	$280.67B	0.64	1.84 million shs	1.61 million shs
SDZNY Sandoz Group	$60.20 +1.3%	$59.89	$35.61 ▼ $63.72	$26.49B	0.54	31,770 shs	26,221 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAH Cardinal Health	+0.84%	-0.16%	+4.74%	-4.73%	+40.09%
COR Cencora	+1.08%	-1.11%	+5.51%	+2.83%	+40.61%
LLY Eli Lilly and Company	-0.13%	+10.65%	+16.24%	+7.28%	-6.02%
MCK McKesson	+1.26%	-2.91%	+9.18%	+3.16%	+55.07%
NVS Novartis	-0.59%	+2.64%	+1.40%	+7.01%	+15.55%
SDZNY Sandoz Group	-1.82%	-0.34%	-3.24%	+6.14%	+42.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAH Cardinal Health	$156.37 -0.2%	$152.03	$106.98 ▼ $168.44	$37.12B	0.71	2.42 million shs	17,341 shs
COR Cencora	$307.20 -0.5%	$295.45	$220.03 ▼ $315.23	$59.61B	0.63	1.56 million shs	14,186 shs
LLY Eli Lilly and Company	$851.33 +0.9%	$736.97	$623.78 ▼ $937.00	$806.14B	0.47	4.10 million shs	130,460 shs
MCK McKesson	$748.83 -0.2%	$704.07	$492.39 ▼ $776.14	$92.93B	0.52	868,717 shs	13,491 shs
NVS Novartis	$132.85 +1.0%	$124.18	$96.06 ▼ $133.55	$280.67B	0.64	1.84 million shs	1.61 million shs
SDZNY Sandoz Group	$60.20 +1.3%	$59.89	$35.61 ▼ $63.72	$26.49B	0.54	31,770 shs	26,221 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAH Cardinal Health	+0.84%	-0.16%	+4.74%	-4.73%	+40.09%
COR Cencora	+1.08%	-1.11%	+5.51%	+2.83%	+40.61%
LLY Eli Lilly and Company	-0.13%	+10.65%	+16.24%	+7.28%	-6.02%
MCK McKesson	+1.26%	-2.91%	+9.18%	+3.16%	+55.07%
NVS Novartis	-0.59%	+2.64%	+1.40%	+7.01%	+15.55%
SDZNY Sandoz Group	-1.82%	-0.34%	-3.24%	+6.14%	+42.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAH Cardinal Health	2.80	Moderate Buy	$166.00	6.16% Upside
COR Cencora	2.75	Moderate Buy	$320.00	4.17% Upside
LLY Eli Lilly and Company	2.64	Moderate Buy	$943.00	10.77% Upside
MCK McKesson	2.88	Moderate Buy	$829.08	10.72% Upside
NVS Novartis	2.10	Hold	$120.33	-9.42% Downside
SDZNY Sandoz Group	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest CAH, COR, LLY, MCK, NVS, and SDZNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2025	COR Cencora	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$340.00
10/8/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$875.00 ➝ $948.00
10/6/2025	CAH Cardinal Health	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$186.00 ➝ $187.00
10/3/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,028.00 ➝ $1,023.00
10/1/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$700.00 ➝ $800.00
9/27/2025	CAH Cardinal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
9/27/2025	COR Cencora	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
9/27/2025	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
9/27/2025	MCK McKesson	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
9/27/2025	NVS Novartis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
9/26/2025	MCK McKesson	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$821.00 ➝ $853.00

(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAH Cardinal Health	$222.58B	0.17	$11.76 per share	13.30	($11.04) per share	-14.16
COR Cencora	$293.96B	0.20	$20.00 per share	15.36	$4.04 per share	76.04
LLY Eli Lilly and Company	$45.04B	17.89	$14.34 per share	59.37	$15.03 per share	56.64
MCK McKesson	$359.05B	0.26	$39.25 per share	19.08	($13.52) per share	-55.39
NVS Novartis	$50.32B	5.58	$10.75 per share	12.36	$21.59 per share	6.15
SDZNY Sandoz Group	$10.36B	2.56	$2.66 per share	22.65	$18.56 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAH Cardinal Health	$1.56B	$6.45	24.22	17.47	1.31	0.70%	-74.45%	4.14%	10/30/2025 (Estimated)
COR Cencora	$1.51B	$9.72	31.63	18.20	1.43	0.60%	267.36%	4.31%	11/5/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	55.67	27.36	1.18	25.91%	92.72%	16.89%	10/30/2025 (Estimated)
MCK McKesson	$3.30B	$25.08	29.79	20.44	1.34	0.84%	-196.66%	5.66%	11/5/2025 (Estimated)
NVS Novartis	$11.94B	$6.87	19.34	15.08	1.83	25.64%	41.08%	16.83%	10/28/2025 (Estimated)
SDZNY Sandoz Group	$1M	N/A	0.00	18.13	1.06	N/A	N/A	N/A	N/A

Latest CAH, COR, LLY, MCK, NVS, and SDZNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2025	Q4 2025	COR Cencora	$3.80	N/A	N/A	N/A	$83.36 billion	N/A
11/5/2025	Q2 2026	MCK McKesson	$8.84	N/A	N/A	N/A	$103.80 billion	N/A
10/30/2025	Q1 2026	CAH Cardinal Health	$2.22	N/A	N/A	N/A	$59.41 billion	N/A
10/30/2025	Q3 2025	LLY Eli Lilly and Company	$6.42	N/A	N/A	N/A	$16.09 billion	N/A
10/28/2025	Q3 2025	NVS Novartis	$2.28	N/A	N/A	N/A	$13.70 billion	N/A
8/12/2025	Q4 2025	CAH Cardinal Health	$2.03	$2.08	+$0.05	$1.00	$60.91 billion	$60.16 billion
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q3 2025	COR Cencora	$3.79	$4.00	+$0.21	$3.52	$80.34 billion	$80.66 billion
8/6/2025	Q1 2026	MCK McKesson	$8.33	$8.26	-$0.07	$6.25	$95.93 billion	$97.83 billion
7/17/2025	Q2 2025	NVS Novartis	$2.38	$2.42	+$0.04	$2.06	$13.94 billion	$14.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAH Cardinal Health	$2.04	1.30%	N/A	31.63%	29 Years
COR Cencora	$2.20	0.72%	N/A	22.63%	15 Years
LLY Eli Lilly and Company	$6.00	0.70%	N/A	39.22%	11 Years
MCK McKesson	$3.28	0.44%	N/A	13.08%	17 Years
NVS Novartis	$2.60	1.96%	N/A	37.85%	N/A
SDZNY Sandoz Group	$0.44	0.73%	N/A	N/A	N/A

Latest CAH, COR, LLY, MCK, NVS, and SDZNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/15/2025	CAH Cardinal Health	quarterly	$0.5107	1.29%	10/1/2025	10/1/2025	10/15/2025
7/30/2025	MCK McKesson	quarterly	$0.82	0.47%	9/2/2025	9/2/2025	10/1/2025
8/6/2025	COR Cencora	quarterly	$0.55	0.75%	8/15/2025	8/15/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAH Cardinal Health	N/A	0.94	0.50
COR Cencora	3.64	0.90	0.53
LLY Eli Lilly and Company	1.86	1.28	1.00
MCK McKesson	N/A	0.88	0.49
NVS Novartis	0.53	0.82	0.62
SDZNY Sandoz Group	0.62	1.29	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAH Cardinal Health	87.17%
COR Cencora	97.52%
LLY Eli Lilly and Company	82.53%
MCK McKesson	85.07%
NVS Novartis	13.12%
SDZNY Sandoz Group	0.06%

Insider Ownership

Company	Insider Ownership
CAH Cardinal Health	0.12%
COR Cencora	10.80%
LLY Eli Lilly and Company	0.14%
MCK McKesson	0.08%
NVS Novartis	0.01%
SDZNY Sandoz Group	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAH Cardinal Health	57,700	237.58 million	237.30 million	Optionable
COR Cencora	46,000	193.88 million	172.94 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
MCK McKesson	45,000	124.38 million	124.28 million	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
SDZNY Sandoz Group	23,406	440.00 million	N/A	Not Optionable

CAH, COR, LLY, MCK, NVS, and SDZNY Headlines

Recent News About These Companies

Sandoz Group (OTCMKTS:SDZNY) Stock Price Down 1.8% - Should You Sell?

October 8 at 4:09 AM | marketbeat.com

Sandoz Group (OTCMKTS:SDZNY) Shares Gap Down - Should You Sell?

October 1, 2025 | marketbeat.com

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

September 29, 2025 | zacks.com

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

September 24, 2025 | businesswire.com

Sandoz Group (OTCMKTS:SDZNY) Sees Large Volume Increase - Time to Buy?

September 19, 2025 | marketbeat.com

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) Short Interest Update

September 17, 2025 | marketbeat.com

Sandoz price target raised to CHF 55 from CHF 46 at JPMorgan

September 16, 2025 | msn.com

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

September 12, 2025 | zacks.com

Regeneron settles patent dispute with Sandoz over Eylea biosimilar

September 9, 2025 | msn.com

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

August 27, 2025 | zacks.com

Kepler Capital Remains a Buy on Sandoz Group Ltd (SDZXF)

August 17, 2025 | theglobeandmail.com

Sandoz Group: Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

August 12, 2025 | finanznachrichten.de

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

August 12, 2025 | globenewswire.com

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

August 11, 2025 | zacks.com

Sandoz Group Ltd’s Strategic Growth Amid Market Challenges

August 9, 2025 | theglobeandmail.com

Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

August 7, 2025 | globenewswire.com

Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports

August 4, 2025 | reuters.com

Sandoz to acquire Just-Evotec Biologics from Evotec for $300M

July 30, 2025 | msn.com

Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site

July 30, 2025 | pharmiweb.comP

Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site

July 30, 2025 | pharmiweb.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CAH, COR, LLY, MCK, NVS, and SDZNY Company Descriptions

Cardinal Health NYSE:CAH

$156.37 -0.28 (-0.18%)

As of 09:54 AM Eastern

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Cencora NYSE:COR

$307.20 -1.52 (-0.49%)

As of 09:54 AM Eastern

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Eli Lilly and Company NYSE:LLY

$851.33 +7.70 (+0.91%)

As of 09:54 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

McKesson NYSE:MCK

$748.83 -1.30 (-0.17%)

As of 09:54 AM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Novartis NYSE:NVS

$132.85 +1.30 (+0.99%)

As of 09:54 AM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sandoz Group OTCMKTS:SDZNY

$60.20 +0.77 (+1.30%)

As of 09:34 AM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAH, COR, LLY, MCK, NVS, and SDZNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAH, COR, LLY, MCK, NVS, and SDZNY Earnings

Compare Dividends

Latest CAH, COR, LLY, MCK, NVS, and SDZNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAH, COR, LLY, MCK, NVS, and SDZNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CAH, COR, LLY, MCK, NVS, and SDZNY Company Descriptions

Cardinal Health NYSE:CAH

Cencora NYSE:COR

Eli Lilly and Company NYSE:LLY

McKesson NYSE:MCK

Novartis NYSE:NVS

Sandoz Group OTCMKTS:SDZNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools